Quoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals, Ltd. is a late-stage specialty pharmaceutical company focused on developing and commercializing therapeutics for rare and orphan diseases in the United States. Its lead product, QRX003, is a topical lotion in Phase 2 for Netherton syndrome, Phase 1 for peeling skin syndrome, and preclinical for SAM syndrome and ichthyosis. The company also develops QRX008 for scleroderma (preclinical) and QRX009 for microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. Founded in 2018 and based in Ashburn, Virginia, Quoin Pharmaceuticals is a subsidiary of Skinvisible, Inc. and has a research agreement with Queensland University of Technology.